Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Moodys
Mallinckrodt
Merck
McKesson

Last Updated: January 23, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,481,598


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,481,598 protect, and when does it expire?

Patent 8,481,598 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 8,481,598
Title:Stable dosage forms of levomilnacipran
Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
Inventor(s): Surana; Rahul (Commack, NY), Divi; Murali (Ronkonkoma, NY), Chhettry; Anil (Holtsville, NY)
Assignee:
Application Number:13/006,993
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,481,598
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,481,598

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-001 Jul 25, 2013 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Try it Free
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Try it Free
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-003 Jul 25, 2013 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Try it Free
Allergan FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-004 Jul 25, 2013 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,481,598

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2779711 ⤷  Try it Free
Canada 2790933 ⤷  Try it Free
European Patent Office 2496079 ⤷  Try it Free
European Patent Office 2536688 ⤷  Try it Free
Japan 2013510176 ⤷  Try it Free
Japan 2013517290 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Dow
McKesson
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.